Bristol Myers Squibb - U.S. Food and Drug Administration …
WEB8 hours ago · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an oral medication for the treatment of schizophrenia in adults.
FDA approves Bristol Myers Squibb's schizophrenia drug
WEB20 hours ago · The Food and Drug Administration approved Bristol Myers Squibb’s highly anticipated schizophrenia drug, the first novel type of treatment for the debilitating, chronic mental disorder in more...
Bristol Myers wins US FDA approval for new type of schizophrenia drug
WEB20 hours ago · Sept 26 (Reuters) - The U.S. Food and Drug Administration approved Bristol Myers Squibb's (BMY.N) schizophrenia drug late on Thursday, making it the first new type of antipsychotic...
US FDA approves Bristol Myers' schizophrenia drug
WEB9 hours ago · (Reuters) -The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades.
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEBApr 28, 2022 · PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Camzyos™ (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules) for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy ...
FDA approves Bristol Myers Squibb's new schizophrenia drug
WEB4 hours ago · The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated schizophrenia drug, Cobenfy. It’s the first novel treatment for the ...
Bristol Myers Squibb - U.S. Food and Drug Administration …
WEBNov 15, 2023 · U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
Bristol Myers (BMY) Gets US Nod for First New Schizophrenia Drug …
WEB20 hours ago · The medication, to be sold under the name Cobenfy, gained Food and Drug Administration clearance Thursday to treat patients with the illness that often produces hallucinations and delusions.
U.S. Food and Drug Administration Approves Bristol Myers …
WEB18 hours ago · PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved COBENFY™ (xanomeline and trospium chloride), an...
Bristol-Myers wins FDA nod for first-of-its-kind antipsychotic - MSN
WEBThe U.S. Food and Drug Administration (FDA) on Thursday approved Cobenfy (xanomeline and trospium chloride), developed by Bristol-Myers Squibb (NYSE:BMY), as a novel treatment for adults...
Skip to content